1Haase D,Germing U,Schanz J,et al.New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes:evidence from a core dataset of 2124 patients[J].Blood,2007;110(13):4385-95.
3Ebert BL,Galili N,Tamayo P,et al.An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome[J].PLoS Med,2008;5(2):312-22.
4Ades L,Boehrer S,Prebet T,et al.Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion:results of a phase 2 study[J].Blood,2009;113(17):3947-52.
5List A,Dewald G,Bennett J,et al.Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion[J].N Engl J Med,2006;355:1456-65.
6Raza A,Reeves JA,Feldman EJ,et al.Phase 2 study of lenalidomide in transfusion-dependent,low-risk,and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q[J].Blood,2008;111(1):86-93.
7Sekeres MA,Maciejewski JP,Giagounidis AAN,et al.Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes[J].J Clin Oncol,2008;26(36):5943-9.
2Kotla V,Goel S,Nischal S,et al.Mechanism of action of lenalidomide in hematological malignancies.J Hematol Oncol,2009;2(36):1-10.
3Ferrajoli A,Lee BN,Schlette EJ,et al.Lenalidomide inducescomplete and partial remissions in patients with relapsed andrefractory chronic lymphocytic leukemia.Blood,2008;111(11):5291-5297.
4Verhelle D,Corral LG,Wong K,et al.Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expandingnormal CD34+progenitor cells.Cancer Res,2007;67(2):746-755.
5Vallet S,Palumbo A,Raje N,et al.Thalidomide andlenalidomide:Mechanism-based potential drug combinations.LeukLymphoma,2008;49(7):1238-1245.
6Jakubikova J,Adamia S,Kost-Alimova M,et al.Lenalidomidetargets clonogenic side population in multiple myeloma:pathophysiologic and clinical implications.Blood,2011;117(17):4409-4419.
7Lopez-Girona A,Heintel D,Zhang LH,et al.Lenalidomidedownregulates the cell survival factor,interferon regulatory factor-4,providing a potential mechanistic link for predicting response.BrJ Haematol,2011;154(3):325-336.
8Boll B,Borchmann P,Topp MS,et al.Lenalidomide in patientswith refractory or multiple relapsed Hodgkin lymphoma.Br JHaematol,2009;148(3):480-490.
